Project Grant R44AI192170
Award Date
6/23/25
Completion Date
5/31/28
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Mucommune LLC (NWVPL2L4JMN8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Topaz Biosciences, Inc. to discover and optimize novel endolysins that can selectively target Gardnerella vaginalis, the primary bacterial species associated with bacterial vaginosis (BV). The goal is to develop improved endolysins that are more active, thermostable, and pH tolerant than...
This $1,132,258 Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 Aging Research supports the development of a hormone-free prebiotic muco-adhesive gel for the treatment of vaginal atrophy in post-menopausal women. The awardee, Moremme VA LLC, is working to optimize the loading and release of natural bioactives in the gel formulation, assess its safety and tolerability in human vaginal tissue models, and evaluate its efficacy in reversing signs of vaginal atrophy...
This $1,670,110 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel, multi-compartment intravaginal ring (IVR) for the prevention of genital herpes (HSV) and unintended pregnancy. The key products and services funded under this award include: Evaluating a panel of small-molecule inhibitors of soluble adenylyl cyclase (SAC) to select a lead...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,533,177 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to conduct a Phase 1 randomized, placebo-controlled safety study of MUCOCEPT-CVN, a live biotherapeutic product containing genetically engineered Lactobacillus jensenii 1153-1666 that secretes an HIV entry inhibitor. The study aims to evaluate...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,000.00 to Case Western Reserve University to conduct research on defining the role of single-cell heterogeneity in bacterial vaginosis (BV). The overarching goal is to identify aspects of diversity that impact BV and provide insights into new strategies for prevention, treatment, and diagnosis. The...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,564,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on identifying drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa. The project will run from August 2024 through June 2029. The grant supports several key products and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $700,350 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Case Western Reserve University (CWRU) to define the neovaginal microbiome in transgender women who have undergone or are scheduled to undergo gender-affirming vaginoplasty. The goal is to investigate associations between the neovaginal microbiome, genital inflammation, and clinical outcomes including gynecological...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $288,360 Project Grant under CFDA 93.855 (Allergy and Infectious Diseases Research) to Biological Mimetics, Inc. to develop a novel vaccine candidate that stimulates immune protection against multi-drug resistant Acinetobacter baumannii (MDR-AB). The Phase I project aims to (1) identify and characterize key immunogenic components of MDR-AB that lead to protective immunity, (2) develop a prototype vaccine formulation, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on elucidating the role of Akkermansia muciniphila in Group B Streptococcal (GBS) vaginal colonization and ascending infection. The $148,568 award will support research to investigate the specific mechanisms by which A. muciniphila promotes GBS interaction with human vaginal epithelial cells, potentially...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant under CFDA 93.855, Allergy and Infectious Diseases Research, to Dare Bioscience, Inc., a self-certified small disadvantaged business located in San Diego, CA. The grant supports the development of DARE-HPV, an innovative anti-viral vaginal insert to address the health threat posed by persistent high-risk human papillomavirus (HR-HPV) infections, which are associated with cervical cancers. The...